Key result
Adipose tissue dysfunction and insulin resistance drive cardiometabolic syndrome, increasing cardiovascular disease and diabetes risk.
Design
Review
This paper reviews the pharmacological management, public health strategies, and future directions for cardiometabolic syndrome.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2026) studied this question. Cardiometabolic syndrome is driven by adipose tissue dysfunction and insulin resistance, resulting in an increased risk of cardiovascular disease, type 2 diabetes, and chronic conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: